|
| N-[2-[4-(benzimidazol-1-yl)anilino]-2-oxoethyl]-3-chloro-1-benzothiophene-2-carboxamide |
|
Salmonella
Yersinia |
TTSS (SPI-1 encode)
TTSS (Type III secretion system) |
Preclinical (in vitro)
Preclinical (in vivo) |
Boonyom R, et al. 2022. J Genet Eng Biotechnol
Swietnicki W, et al. 2011. PLoS One |
|
| N-[4-(1-hydroxy-6-nitrobenzimidazol-2-yl)phenyl]-4-(1,3-oxazol-5-yl)benzamide |
|
Yersinia |
TTSS (Type III secretion system) |
Preclinical (in vivo) |
Garrity-Ryan LK, et al. 2010. Infect Immun |
|
| (2Z)-2-(3-chloro-5-ethoxy-4-hydroxybenzylidene)-7,8-dimethyl[1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one |
|
Pseudomonas
Yersinia |
TTSS (Type III secretion system)
TTSS (Type III secretion system) |
Preclinical (in vitro)
Preclinical (in vitro) |
Harmon DE, et al. 2010. Antimicrob Agents Chemother
|
|
| (E)-3-(4-fluorophenyl)-N-[4-(1-hydroxy-5-methyl-6-nitrobenzimidazol-2-yl)phenyl]prop-2-enamide |
|
Yersinia |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Kim OK, et al. 2009. J Med Chem |
|
| (E)-3-(4-fluorophenyl)-N-[4-(1-hydroxy-6-nitrobenzimidazol-2-yl)phenyl]prop-2-enamide |
|
Pseudomonas
Yersinia
Yersinia |
TTSS (Type III secretion system)
TTSS (Type III secretion system)
TTSS (Type III secretion system) |
Preclinical (in vitro)
Preclinical (in vitro)
Preclinical (in vivo) |
Marsden AE, et al. 2016. Antimicrob Agents Chemother
Kim OK, et al. 2009. J Med Chem
Garrity-Ryan LK, et al. 2010. Infect Immun |
|
| (E)-N-[4-(1-hydroxy-6-nitrobenzimidazol-2-yl)phenyl]-3-(4-methoxyphenyl)prop-2-enamide |
|
Yersinia |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Kim OK, et al. 2009. J Med Chem |
|
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
